Clinical Trial

BmemHLA : Origins of the Heterogeneity of the Anti-HLA Memory B Cells in Kidney Transplantation

Study acronym: BmemHLA
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 28, 2025 (before its estimated June 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will describe the transcriptomic and phenotypic characteristics of anti-HLA memory B cells by comparing five groups of patients awaiting renal transplantation: patients with a single history of pregnancy, transfusion or failure of a first renal transplant requiring transplantectomy within 3 months of transplantation, or after 3 months, and patients without an immunizing allogeneic event. The hypothesis is that these five contexts induce different types of memory B cells with different modalities of reactivation and post-transplant pathogenicity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-25; most recent amendment 2025-05-26.
Trial Details
NCT Number NCT06956469
Lead Sponsor University Hospital, Bordeaux
Conditions Kidney Transplantation, Immunology
Enrollment 75 participants
Start Date 2025-06-15
Primary Completion 2025-06-15 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-05-28